A Leading Microcap
Investment Bank
Specializing in Reverse Mergers, PIPEs,
M&A, Bridge Financing & Private Equity
  • Phase Rx
  • PallAdium Capital Advisor
  • PallAdium Capital Advisor
  • PallAdium Capital Advisor
  • PallAdium Capital Advisor
  • PallAdium Capital Advisor

PhaseRx, Inc.

PhaseRx Tombstone (IPO)

PhaseRx is Unlocking the Power of RNA Therapeutics

PhaseRx is focused on advancing the potential of RNA therapeutics generated from its breakthrough SMARTT Polymer Technology®

PhaseRx is dedicated to developing RNA therapeutics that hold promise for treatment of orphan diseases for which few, if any, therapeutic options are available. To date, development of RNA therapeutics has been hindered by the lack of effective delivery technology. PhaseRx was founded to solve the critical challenge in RNA delivery: the need for a versatile, developable system that can be administered systemically and deliver RNA drugs into the cell where they can reach and modulate drug targets.

PhaseRx’s propriety SMARTT Polymer Technology® (SMARTT) addresses these challenges, providing a breakthrough platform for the development of novel RNA-based drugs.

SMARTT is designed to provide a robust, developable, and versatile RNA delivery system to fuel our product development pipeline and enable our pharmaceutical and biotechnology partners to take their novel molecules forward into clinical development. With a comprehensive intellectual property portfolio, an experienced management team, top-tier investor syndicate and a breakthrough RNA delivery system, PhaseRx is well positioned to advance its therapeutic RNA candidates and partner its innovative technology platform to expand future development and commercial opportunities.

PhaseRx was founded by Robert Overell, President and CEO, together with Patrick Stayton and Allan Hoffman of the University of Washington, Oliver Press of Fred Hutchinson Cancer Research Center, and Paul Johnson, the Company’s Chief Scientific Officer. PhaseRx was conceived on the basis of using novel polymer technology to deliver siRNA. The Company’s proprietary technology is a new type of synthetic, multi-functional polymer exclusively licensed from the University of Washington. The polymers come from the laboratories of Patrick Stayton and Allan Hoffman at the University of Washington, which have world-class expertise in fine-tuning the polymers to meet intracellular and in vivo delivery needs.